Celldex Therapeutics(CLDX)
HAMPTON, NJBiotechnology
Focus: Celldex is a mid-cap public biotech (NASDAQ: CLDX) with 501–1,000 employees focused on immunotherapy, oncology, and vaccines using small molecules, biologics, and vaccine platforms. The company is in early-stage development with minimal revenue ($7M FY2025) and operates as a clinical-stage pipeline engine.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
0
About Celldex Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Celldex Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$7M
Pipeline & Clinical Trials
glembatumumab vedotin
Metastatic gpNMB Expressing Triple Negative Breast CancerClinical Trials (1)
NCT03067935Individual Patient Expanded Access-Glembatumumab Vedotin
N/AHelp build intelligence for Celldex Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.